Market Place
Sourcing Support
MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
12 Nov 2024 //
BUSINESSWIRE
MEI Pharma Reports Fiscal Year End 2024 Cash Position
19 Sep 2024 //
BUSINESSWIRE
MEI Pharma Engages Oppenheimer To Evaluate Strategic Alternatives
12 Aug 2024 //
BUSINESSWIRE
MEI Pharma, after failed Infinity merger last year, to strategic alternatives
22 Jul 2024 //
FIERCE BIOTECH
MEI Pharma to Consider Strategic Alternatives
22 Jul 2024 //
BUSINESSWIRE
MEI Pharma Q3 FY2024 Results, Operational Highlights
09 May 2024 //
BUSINESSWIRE
MEI Pharma: ME-344 + Avastin® Data In Colorectal Cancer
11 Apr 2024 //
BUSINESSWIRE
MEI Pharma Aligned On Voruciclib, ME-344 Strategy
11 Apr 2024 //
BUSINESSWIRE
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
10 Apr 2024 //
BUSINESSWIRE
MEI Update from Study Evaluating Voruciclib with Venetoclax in Patients with AML
26 Mar 2024 //
BUSINESSWIRE
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results
13 Feb 2024 //
BUSINESSWIRE
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344
16 Jan 2024 //
BUSINESSWIRE
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
11 Dec 2023 //
BUSINESSWIRE
MEI Pharma Reports First Quarter Fiscal Year 2024 Results
09 Nov 2023 //
BUSINESSWIRE
MEI Pharma to Present at the Stifel 2023 Healthcare Conference
08 Nov 2023 //
BUSINESSWIRE
MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock
06 Nov 2023 //
BUSINESSWIRE
MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023
02 Nov 2023 //
BUSINESSWIRE
MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital
01 Nov 2023 //
BUSINESSWIRE
MEI Pharma Recommends Stockholders Not to Consent
17 Oct 2023 //
BUSINESSWIRE
MEI Pharma Adopts Limited-Duration Stockholder Rights Plan
02 Oct 2023 //
BUSINESSWIRE
MEI Pharma pushes back on activist investors after failed merger with Infinity
29 Sep 2023 //
ENDPTS
MEI Pharma Issues Statement Regarding Anson & Cable Car’s Opportunistic Actions
28 Sep 2023 //
BUSINESSWIRE
MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights
26 Sep 2023 //
BUSINESSWIRE
MEI Pharma to Report 2023 Fiscal Year End Financial Results
21 Sep 2023 //
BUSINESSWIRE
MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car
18 Sep 2023 //
BUSINESSWIRE
MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344
16 Aug 2023 //
BUSINESSWIRE
The Infinity-MEI merger saga ends in shareholders sinking deal
24 Jul 2023 //
FIERCE BIOTECH
MEI Pharma Announces Results of Special Meeting of Stockholders
23 Jul 2023 //
BUSINESSWIRE
MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction
19 Jul 2023 //
BUSINESSWIRE
MEI Pharma Responds to Anson and Cable Car
18 Jul 2023 //
BUSINESSWIRE
MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction
17 Jul 2023 //
BUSINESSWIRE
Infinity Pharma Announces Stockholder Approval of Merger with MEI Pharma
14 Jul 2023 //
BUSINESSWIRE
MEI Pharma Postpones Special Meeting of Shareholders
13 Jul 2023 //
BUSINESSWIRE
MEI Pharma Provides Reminder to Shareholders to Vote FOR Merger With Infinity
11 Jul 2023 //
BUSINESSWIRE
MEI Pharma Reminds Shareholders to Vote FOR Merger with Infinity Pharmaceuticals
07 Jul 2023 //
BUSINESSWIRE
ISS Recommends Infinity Pharma Stockholders Vote FOR the Merger with MEI
05 Jul 2023 //
BUSINESSWIRE
MEI Pharma Mails Letter to Shareholders Reiterating Value with Infinity
29 Jun 2023 //
BUSINESSWIRE
MEI and Infinity Host Webcast Providing Overview to Advance Oncology Candidates
15 Jun 2023 //
BUSINESSWIRE
MEI Pharma Announces Planned Departure of CFO Brian Drazba
13 Jun 2023 //
BUSINESSWIRE
MEI Pharma Announces Planned Departure of CEO Daniel P. Gold
02 Jun 2023 //
BUSINESSWIRE
MEI turns down ‘significantly undervalued’ takeover offer
01 Jun 2023 //
FIERCE BIOTECH
MEI Pharma Board of Directors Rejects Unsolicited Proposal
01 Jun 2023 //
BUSINESSWIRE
Infinity merger with MEI in doubt after surprise buyer makes bid
31 May 2023 //
FIERCE BIOTECH
MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal
30 May 2023 //
BUSINESSWIRE
MEI Pharma Announces Update of PI Study Evaluating CDK9 Inhibitor Voruciclib
23 May 2023 //
BUSINESSWIRE
MEI Pharma Reports Third Quarter Fiscal Year 2023 Results
11 May 2023 //
BUSINESSWIRE
MEI Pharma Announces 1-for-20 Reverse Stock Split
14 Apr 2023 //
BUSINESSWIRE
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement
23 Feb 2023 //
BUSINESSWIRE
MEI Pharma Reports Second Quarter Fiscal Year 2023 Results
09 Feb 2023 //
BUSINESSWIRE
MEI and Kyowa Kirin to discontinue development of zandelisib outside Japan
07 Dec 2022 //
PHARMACEUTICAL-TECHNOLOGY
MEI Pharma Announces Adjournment of Annual Meeting of Stockholders
06 Dec 2022 //
BUSINESSWIRE
As FDA door shuts on its PI3K, MEI Pharma throws in the towel, lays off staff
06 Dec 2022 //
ENDPTS
FDA feedback drives MEI, Kyowa to halt blood cancer program
06 Dec 2022 //
FIERCEBIOTECH
MEI Pharma & Kyowa Kirin Announce Discontinuation of Zandelisib Outside of Japan
06 Dec 2022 //
BUSINESSWIRE
Kyowa Kirin and MEI Pharma report data from Phase II lymphoma trial
21 Nov 2022 //
CLINICALTRIALSARENA
MEI, Kyowa confirm phase 2 cancer efficacy with fresh data drop
19 Nov 2022 //
FIERCEPHARMA
MEI Reports First Quarter Fiscal Year 2023 Results and Operational Highlights
14 Nov 2022 //
BUSINESSWIRE
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
03 Oct 2022 //
BUSINESSWIRE
MEI Pharma Announces Changes to Board of Directors
22 Sep 2022 //
BUSINESSWIRE
